Results 161 to 170 of about 3,500 (185)
Some of the next articles are maybe not open access.
Filgotinib for moderately to severely active ulcerative colitis
Expert Review of Gastroenterology & Hepatology, 2022Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.Pubmed, Scopus, and Embase databases were searched for all relevant studies ...
Alessandro Mannucci +4 more
openaire +2 more sources
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease
Immunotherapy, 2023Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD).
Fanizza J +11 more
openaire +3 more sources
Filgotinib for the treatment of Crohn’s disease
Expert Opinion on Investigational Drugs, 2018Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence.
Labetoulle, Remi +2 more
openaire +4 more sources
Filgotinib for the Treatment of Refractory Collagenous Colitis
Journal of Crohn's and Colitis, 2023Tomoyoshi Shibuya, Akihito Nagahara
openaire +2 more sources
Filgotinib for ulcerative colitis
Nature Reviews Gastroenterology & Hepatology, 2021openaire +2 more sources
Le filgotinib (Jyseleca®), un inhibiteur des Janus kinases
Actualités Pharmaceutiques, 2022Jacques Buxeraud, Sébastien Faure
openaire +1 more source
Rheumatoide Arthritis: Filgotinib mit gutem Sicherheitsprofil
Orthopädie & Rheuma, 2021openaire +1 more source